Repurposing antidiabetic drugs for cancer treatment holds great potential, driven by their well-established safety profiles, expedited development timelines, potential cost-effectiveness, and targeting pathways such as PI3K/AKT/mTOR, Wnt/β-catenin, JAK/STAT in cancer, and AMPK and PPARγ in diabetes to accelerate clinical application. This evidence concerns the gene PPARG and diabetes mellitus.